BLGO — BioLargo Cashflow Statement
0.000.00%
Last trade - 00:00- $102.10m
- $96.50m
- $12.23m
- 76
- 13
- 94
- 63
Annual cashflow statement for BioLargo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.4 | -9.7 | -6.89 | -5.13 | -4.65 |
| Depreciation | |||||
| Non-Cash Items | 6.93 | 5.42 | 2.69 | 2.58 | 3.26 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.025 | 0.069 | 0.249 | -0.25 | -1.08 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.42 | -4.15 | -3.94 | -2.76 | -2.37 |
| Capital Expenditures | -0.035 | -0.023 | -0.034 | -0.271 | -0.478 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -0.1 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.035 | -0.123 | -0.034 | -0.271 | -0.478 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.47 | 4.34 | 4.23 | 3.96 | 4.66 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0 | 0.061 | 0.246 | 0.889 | 1.69 |